Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Only patients who lost 5% body weight during the 12-week intensive lifestyle lead-in period entered the 72-week randomized treatment period
Some patients find that spacing injections to every other week reduces the psychological burden of frequent needle use while still achieving meaningful weight reduction during the maintenance phase of treatment
Due to its structural adjustment, IGF-1 LR3 has a much longer half-life and results may persist in the bloodstream for up to 120 times longer
Fierce Pharma [Preprint] Samms RJ et al (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Visit TrimRx Assessment Quiz to get started
While practical challenges including cost, access, and manufacturing constraints currently limit the widespread adoption of tirzepatide, the clinical evidence suggests that dual agonism represents the future direction of metabolic therapy
